Newsroom

GOTEMBURGO, Suecia--(BUSINESS WIRE)--Oticon Medical anuncia hoy el lanzamiento de SmartCharger para la gama Ponto 5, su primera solución recargable para procesadores de sonido percutáneos, lo que supone un nuevo avance en cuanto a comodidad y portabilidad para los usuarios de sistemas auditivos osteointegrados. Energía para la gama Ponto 5 El lanzamiento de SmartCharger destaca el compromiso constante de Oticon Medical con la gama Ponto, que incluye el Ponto 5 SuperPower, el procesador de sonid...

GÖTEBORG, Suède--(BUSINESS WIRE)--Oticon Medical annonce aujourd’hui le lancement du SmartCharger pour la gamme Ponto 5, présentant ainsi sa première solution rechargeable pour les processeurs sonores percutanés et marquant une nouvelle avancée en matière de confort et de portabilité pour les utilisateurs de systèmes auditifs à ancrage osseux. Alimenter la gamme Ponto 5 Le lancement du SmartCharger souligne l’engagement continu d’Oticon Medical envers la gamme Ponto, qui comprend le Ponto 5 Sup...

GOTHENBURG, Svezia--(BUSINESS WIRE)--Oticon Medical oggi annuncia il lancio di SmartCharger per la serie Ponto 5, presentando la sua prima soluzione ricaricabile per processori del suono percutanei e segnando una nuova fase nella comodità e portabilità per gli utenti dei sistemi acustici ancorati all'osso. L'alimentazione della serie Ponto 5 Il lancio di SmartCharger sottolinea l'impegno continuo di Oticon Medical nella serie Ponto, che comprende Ponto 5 SuperPower, il processore acustico ad an...

GÖTEBORG, Schweden--(BUSINESS WIRE)--Oticon Medical gibt heute die Markteinführung des SmartChargers für die Ponto-5-Familie bekannt. Damit stellt das Unternehmen seine erste wiederaufladbare Lösung für perkutane Soundprozessoren vor und markiert einen neuen Meilenstein in Sachen Komfort und Mobilität für Nutzer von knochenverankerten Hörsystemen. Stromversorgung für die Ponto-5-Familie Die Einführung des SmartChargers unterstreicht das anhaltende Engagement von Oticon Medical für die Ponto-Fam...

GÖTEBORG, Zweden--(BUSINESS WIRE)--Oticon Medical kondigde vandaag de lancering aan van de SmartCharger voor de Ponto 5-reeks. Hiermee introduceert het zijn eerste herlaadbare oplossing voor percutane geluidsprocessoren en markeert een nieuwe stap in praktisch gemak en draagbaarheid voor gebruikers van botverankerde hoorsystemen. Versterking van de Ponto 5-reeks De lancering van de SmartCharger is een getuigenis van de niet-aflatende inzet van Oticon Medical voor de Ponto-reeks, die onder ander...

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News : Sensorion (FR001401A9Z0 – ALSEN) (« la Société »), société de biotechnologie pionnière au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer l'audition et traiter et prévenir les troubles de l'audition, publie aujourd'hui ses résultats semestriels 2026, fait un point sur son actualité et annonce la mise à disposition de son rapport semestriel. « Je suis ravi d'avoir rejoint Sensorion...

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announced the availability of its half-year report. “I am delighted to have joined Sensorion at such an exciting time, as SENS-601 enters the clinic...

SINGAPORE--(BUSINESS WIRE)--Hafnia Limited ("Hafnia", the "Company", OSE ticker code: "HAFNI", NYSE ticker code: "HAFN") advises that the Extraordinary General Meeting was held earlier today on 23 September 2026 at 10:00 a.m. (Singapore time) at the registered office of the Company 10 Pasir Panjang Road, Mapletree Business City #18-01, Singapore 117438. The following resolution was passed: To appoint Mr. Mikael Øpstun Skov as a Director of the Company. The minutes of the Extraordinary General M...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by...